Minerva Neurosciences NERV
NASDAQ NERV
$4.43 -0.26 (-5.54%)
At close: Sep 4, 2026 · 4:00 PM EDT

Minerva Neurosciences (NERV) Total Current Liabilities (2013 - 2026)

Minerva Neurosciences' (NERV) quarterly Total Current Liabilities came in at $4.5 million in Q1 2026, up 130.19% YoY from $1.9 million in Q1 2025, and up 95.69% on a QoQ basis from $2.3 million in Q4 2025.

Analysis

Minerva Neurosciences (NERV) Total Current Liabilities (2013 - 2026) Analysis & Trends

Minerva Neurosciences (NERV) has 14 years of Total Current Liabilities data on file, last reported at $4.5 million in Q1 2026.

  • Quarterly Total Current Liabilities rose 130.19% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (up 130.19% YoY) and the FY2025 annual result came in at $2.3 million, down 19.26% from the prior year.
  • Total Current Liabilities climbed to $4.5 million in Q1 2026, from $2.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $4.5 million in Q3 2024 to a low of $1.4 million in Q4 2022.
  • A 5-year average of $2.9 million and a median of $2.8 million in 2024 frame the typical range for Total Current Liabilities.
  • Annual changes were most pronounced in 2022 — Total Current Liabilities tumbled 51.13% — and 2023, when it surged 142.49%.
  • Tracing NERV's Total Current Liabilities over 5 years: stood at $1.4 million in 2022, then soared by 142.49% to $3.3 million in 2023, then decreased by 15.08% to $2.8 million in 2024, then slipped by 19.26% to $2.3 million in 2025, then soared by 95.69% to $4.5 million in 2026.
  • The last three Total Current Liabilities figures came in at $4.5 million (Q1 2026), $2.3 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 3.94 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 5.53 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1.58 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 2.53 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 354.06 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 2.12 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 1.51 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 630.93 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 438.74 Mn
10 Minerva Neurosciences 207.37 Mn 207.37 Mn - 3.96 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.96 Mn
Mar 31, 2026 4.48 Mn
Dec 31, 2025 2.29 Mn
Sep 30, 2025 2.67 Mn
Jun 30, 2025 2.53 Mn
Mar 31, 2025 1.95 Mn
Dec 31, 2024 2.84 Mn
Sep 30, 2024 4.48 Mn
Jun 30, 2024 4.20 Mn
Mar 31, 2024 2.83 Mn
Dec 31, 2023 3.34 Mn
Sep 30, 2023 3.35 Mn
Jun 30, 2023 1.91 Mn
Mar 31, 2023 2.50 Mn
Dec 31, 2022 1.38 Mn
Sep 30, 2022 2.20 Mn
Jun 30, 2022 3.41 Mn
Mar 31, 2022 3.25 Mn
Dec 31, 2021 2.82 Mn
Sep 30, 2021 3.08 Mn